Venous Thromboembolism Risk with Janus Kinase Inhibitors: Is it a Class Wide Effect? (Editorial)
Expert Opin Drug Saf. 2022. doi: 10.1080/14740338.2022.2100343
It is too early to conclude that the second-generation JAK inhibitors have a lower VTE risk and caution in patients with VTE risk factors is required.
Following the FDA boxed warning, and similar EMA recommendations, regarding increased risk of thromboembolism and death with use of JAKinibs, this editorial by Jubber, et al., reviews the evidence for VTE risk in JAKinibs, and whether this risk also extends to the
second-generation JAKinibs.
Keywords:
